Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imetelstat Maintenance Therapy After Induction Chemotherapy in Advanced NSCLC
2010-023077-19Phase 2Completed
- Sponsor
- Geron Corporation
- Start
- Dec 2010
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of imetelstat in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Geron Corporation. Primary endpoint: Progression-free survival. Started Dec 2010; status: completed.
02
Drugs
imetelstat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2010-023077-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023077-19.